Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

BARDA Influenza Drug Awardee Biota Relocating to U.S.

by Global Biodefense Staff
April 24, 2012

Australian drug development company Biota announced on Monday that it will be moving to the United States and merging with US-based Nabi Pharmaceuticals to form a new company called Biota Pharmaceuticals. The new enterprise will be headquartered in Rockville, Maryland.

Biota received a $231M USD contract award from the Biomedical Advanced Research and Development Authority (BARDA) in April 2011 for the advanced development of a second-generation flu drug called laninamivir. The drug is a long acting neuraminidase inhibitor that Biota says can both treat and prevent flu infections in fewer doses than currently-available neuraminidase inhibitors. Laninamivir is already approved in Japan but is several years away from approval in the U.S.

The BARDA funding worked to accellerate the timeframe for bringing the drug to market in the U.S. by supporting manufacturing processes and clinical trials stateside.  The contract was part of BARDA’s implementation of the national pandemic influenza preparedness strategy, which includes accelerating the advanced development of new antiviral drugs.

Biota chairman Dr. Jim Fox said that Australian investors had appeared not to have truly appreciated the value of the BARDA award and that the move to the US was designed to achieve better value recognition and liquidity through a stronger US shareholder base.

According to Yahoo Finance, the BARDA contract was almost 1.4 times bigger than Biota’s market capitalisation at the time.  “Just an amazing contract, but the marketplace didn’t really understand that,” Fox said. “We believe the US market will appreciate what we’ve got and better reflect the value of our assets than staying in Australia.”  Biota already has one U.S. approved influenza drug, Relenza, which is marketed by GlaxoSmithKline.

Biota and Nabi are expected to wrap up the deal by September 30, 2012.

Tags: AntiviralsASPRAwardsBARDAHHSInfluenza

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States
Industry News

Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States

September 7, 2022
Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response
Industry News

Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

August 31, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC